Sheena Jonathan sold $479K of NTRA (indirect holdings)

Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $319.30 ($315.26–$324.76, $0.48M total) across 14 trades on 2026-11-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Nov 14, 2026, 2:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The director's sale reduces insider ownership, which may be interpreted as a weak signal by traders, but the modest size limits material impact.

02

Market read

Provides fresh insider‑sale data; relevance is limited to short‑term price pressure considerations.

03

What to watch

Potential upcoming corporate developments or earnings that may offset any short‑term pressure.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Director Sheena Jonathan sold $479K of Natera shares via a 10b5-1 plan, reducing her holdings to 7,500 shares.

Expected impact

potential slight downside as market prices in the director's sale

Evidence & confidence

Sale size is modest ($479K) and executed under a pre‑arranged plan, so impact is likely limited but could nudge the stock lower.

Market effects

Minimal; the sale does not affect the broader genetic‑testing sector.

None; the transaction is company‑specific.

Low; no broader market impact expected.

Counterpoint

The sale could be routine under a 10b5‑1 plan and not indicative of future performance.

Key entities

  • Natera, Inc.

    Genetic testing and diagnostics firm listed on NASDAQ (NTRA).

  • Sheena Jonathan

    Director of Natera who sold shares under a 10b5‑1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.